IGM BIOSCIENCES, INC. (IGMS) News
Filter IGMS News Items
IGMS News Results
|Loading, please wait...|
IGMS News Highlights
- IGMS's 30 day story count now stands at 6.
- Over the past 14 days, the trend for IGMS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about IGMS are NOV, VIEW and COCP.
Latest IGMS News From Around the Web
Below are the latest news stories about IGM BIOSCIENCES INC that investors may wish to consider to help them evaluate IGMS as an investment opportunity.
The Independent Director of IGM Biosciences, Inc. (NASDAQ:IGMS), M. Behrens, Just Bought 27% More Shares
Those following along with IGM Biosciences, Inc. ( NASDAQ:IGMS ) will no doubt be intrigued by the recent purchase of...
MOUNTAIN VIEW, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in fireside chats at three upcoming investor conferences: Stifel Healthcare Conference on Tuesday, November 15 at 9:45 a.m. EST in New YorkJefferies London Healthcare Conference on Thursday, November 17 at 9:45 a.m. GMT/ 4:45 a.m. EST i
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cocrystal Pharma (COCP – Research Report), IGM Biosciences (IGMS – Research Report) and Cidara Therapeutics (CDTX – Research Report) with bullish sentiments. Cocrystal Pharma (COCP) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cocrystal Pharma, with a price target of $42.00. The company's shares closed last Friday at $2.39, close to its 52-week low of $2.05. According to TipRanks.com, Selvaraju has 0 stars on 0-5 stars ranking scale with an average return of -22.7% and a 22.6% success rate.
IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 8.97% and 15.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
– Data from T cell Engager Portfolio for Hematologic Malignancies, Including First Preclinical Data for IGM-2644 and IGM-2537, Selected for Poster Presentations at 2022 ASH Annual Meeting – – Data Update from Phase 1 Trial of Imvotamab Demonstrates Durable Benefit for R/R NHL Patients, with 7/8 Complete Response Patients Tumor Free After 1 Year – MOUNTAIN VIEW, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creati
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
– Companies to Leverage Lead Product Candidate from IGM’s Proprietary IgM Antibody Platform with ZYNLONTA® for Novel Combination Therapy in Relapsed/Refractory B Cell NHL – – Phase 1 Trial Expected to be Initiated in 1Q23 – MOUNTAIN VIEW, Calif. and LAUSANNE, Switzerland, Nov. 02, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, and ADC Therapeutics SA (NYSE: ADCT) today announced that they ha
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
The following slide deck was published by IGM Biosciences, Inc.
BofA Securities has initiated IGM Biosciences (IGMS) with a buy on advantages the company IgM antibodies in development have over existing antibody therapies.
Gainers: Gambling.com Group (GAMB) +6%. IGM Biosciences (IGMS) +5%